CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2021—T2 Biosystems announced that Expert Review of Medical Devices published meta-analysis findings confirming that using the company’s magnetic resonance (T2MR) technology for identification of bloodstream infections provides faster time to detection, faster transition to targeted microbial therapy, faster de-escalation of empirical therapy, and shorter intensive care unit and hospital stay, and with comparable mortality rate versus the current blood culture standard (Giannella M, et al. Online ahead of print April 16, 2021. doi:10.1080/17434440.2021.1919508). Study authors systematically searched Medline, Embase, and Cochrane Central Register of Controlled Trials for randomized trials or observational controlled studies of patients with suspected bloodstream infections receiving a diagnosis with T2MR or blood culture, ultimately including 14 studies.
T2 Biosystems’ FDA-cleared T2Bacteria and T2Candida panels provide results directly from whole blood in three to five hours.